EPISODE · May 12, 2017 · 9 MIN
Arbaclofen in Children and Adolescents with Autism Spectrum Disorder
from NPP BrainPod
Autism Spectrum Disorder is a disorder that has been defined by the medical community, but so far, none of the medications available for ASD treat the core symptoms of the disease, but rather secondary symptoms such as agitation or hyperactivity. Because ASD is genetically linked to Fragile X syndrome, researchers noticed that in a mouse model, the drug arbaclofen reduced what would be core symptoms of autism, such as combatting social avoidance and improving social function. A randomized placebo-controlled trial was conducted to test this idea and the results were recently published in Neuropsychopharmacology. Listen to the latest BrainPod to hear Dr. Jeremy Veenstra-VanderWeele discuss these results! Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Arbaclofen in Children and Adolescents with Autism Spectrum Disorder
No transcript for this episode yet
Similar Episodes
Apr 30, 2026 ·13m
Apr 20, 2026 ·17m
Mar 26, 2026 ·19m
Mar 16, 2026 ·23m
Feb 25, 2026 ·23m